格隆汇12月17日｜加拿大皇家银行：将强生公司目标价从230美元上调至240美元。 ...

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the State Street Health Care Select Sector SPDR ETF ETF (XLV) , a passively managed exchange traded fund launched on December 16, 1998.While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.Investor-friendly, sector ETFs provide many options to gain low ris ...

Johnson & Johnson ( JNJ ) has had a solid 2025 - up ~45% (almost accounting for the total gains made in the past 5 years). The execution and financial numbers have been great too. There is scope for growthI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model v ...

目标价与评级调整 - 美银证券将强生的目标价从204美元上调至220美元 [1] - 美银证券维持对强生的"中性"评级 [1]

A California court has awarded $40 million to two women who claimed their ovarian cancer was a result of prolonged usage of Johnson & Johnson’s talcum-based baby powder. The Los Angeles Superior Court jury distributed the payout, allotting $18 million to Monica Kent and $22 million to both Deborah Schultz and her husband. This decision was made following the conclusion that Johnson & Johnson was aware of the potential harm their products could cause for several years, yet failed to notify consumers.Erik Haa ...

Link Cell Therapies Announces $60M Series A Financing Back to Home Tweet SOUTH SAN FRANCISCO, CA, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing. Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc. , with ...

Key Takeaways JNJ won FDA approval to expand Akeega for BRCA2-mutated metastatic castration-sensitive prostate cancer.The phase III AMPLITUDE study showed the Akeega-prednisone combo cut progression or death risk by 54%.The label expansion moves Akeega into earlier treatment, building on its 2023 approval in resistant disease.Johnson & Johnson (JNJ) announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate dual-action tablet), for a second indication in prostate cancer ...

The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products recei... ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Johnson & Johnson (JNJ) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Johnson & Johnson currently has an ...

Key Takeaways Liquidia Corporation shares have gained 43.9% since an October upgrade, far outpacing the S&P 500's rise.Shares of WDC have climbed 52.8% since its October Outperform upgrade, beating the S&P 500 by a wide margin.JNJ has returned 19.3% over 12 weeks, benefiting from investor demand for quality dividend stocks.The U.S. stock markets ended the week mostly lower, with the tech-heavy Nasdaq Composite and the S&P 500 slipping by 1.49% and 0.28%, respectively, due to a sharp selloff in tech stocks. ...